Atlas Trials

A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine

Clinical trial NCT05458011 · COMPLETED

Trial details

NCT number
NCT05458011
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Migraine
Start date
2022-09-30
Primary completion
2024-01-31
Enrollment
365

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.